GlassScriptPhysician profile
Matthew Bickford
NPI 1750841383
$4,345.46
in general payments reported to CMS, 2019-2025
20 companies · $1,245 in 2025
The $1,245 reported for 2025 was more than what 82% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $214 · 2021: $715 · 2022: $1,081 · 2023: $510 · 2024: $580 · 2025: $1,245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,318 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,317.81 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,006.16 | 2021-2025 | Clareon, Rocklatan, Hydrus Microstent |
| Abbvie INC. | $696.76 | 2022-2025 | Xen Glaucoma Treatment System |
| Bausch & Lomb Americas INC. | $332.06 | 2022-2025 | Miebo, Xiidra, Envista Mx60 Iol |
| Allergan, INC. | $250.63 | 2020-2021 | |
| Sight Sciences, INC. | $243.29 | 2021-2025 | Omni Surgical System, Sion Surgical Instrument |
| Rxsight INC | $241.71 | 2023-2025 | Rxsight Contact Lens, Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Mallinckrodt Hospital Products INC. | $240.60 | 2021-2025 | Acthar |
| Glaukos Corporation | $238.67 | 2021-2022 | |
| Biotissue Holdings INC. | $227.61 | 2020-2025 | |
| Amgen INC. | $209.96 | 2024-2025 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $161.20 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $126.39 | 2024-2025 | |
| New World Medical,INC. | $98.68 | 2025 | Via360, Kahook Dual Blade, Ahmed Glaucoma Valve |
| Harrow Eye, LLC | $93.34 | 2024-2025 | Vevye |
| Johnson & Johnson Surgical Vision, INC. | $74.72 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec Cataract Technology INC. | $32.30 | 2022 | |
| Dompe US, INC. | $21.53 | 2025 | Oxervate |
| Merz Pharmaceuticals, LLC | $18.25 | 2025 | Xeomin |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $16.40 | 2021 | |
| Oyster Point Pharma, INC. | $15.20 | 2025 | Tyrvaya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Bickford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.